Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study
Journal of Gastroenterology · 2024
DOI: 10.1007/s00535-024-02099-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Motoki Makuuchi und 49 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Pyrophosphatases, Mercaptopurine, Genotype, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
This study evaluated the effectiveness of NUDT15 codon 139 genotyping in optimizing thiopurine treatment for inflammatory bowel disease (IBD) in Japan, using real-world data, and aimed to establish genotype-based treatment strategies.
Methods
A retrospective analysis of 4628 IBD patients who underwent NUDT15 codon 139 genotyping was conducted. This study assessed the purpose of the genotyping test and subsequent prescriptions following the obtained results. Outcomes were compared between the Genotyping group (thiopurine with genotyping test) and Non-genotyping group (thiopurine without genotyping test). Risk factors for adverse events (AEs) were analyzed by genotype and prior genotyping status.
Results
Genotyping test for medical purposes showed no significant difference in thiopurine induction rates between Arg/Arg and Arg/Cys genotypes, but nine Arg/Cys patients opted out of thiopurine treatment. In the Genotyping group, Arg/Arg patients received higher initial doses than the Non-genotyping group, while Arg/Cys patients received lower ones (median 25 mg/day). Fewer AEs occurred in the Genotyping group because of their lower incidence in Arg/Cys cases. Starting with < 25 mg/day of AZA reduced AEs in Arg/Cys patients, while Arg/Arg patients had better retention rates when maintaining ≥ 75 mg AZA. Nausea and liver injury correlated with thiopurine formulation but not dosage. pH-dependent mesalamine reduced leukopenia risk in mesalamine users.
Conclusions
NUDT15 codon 139 genotyping effectively reduces thiopurine-induced AEs and improves treatment retention rates in IBD patients after genotype-based dose adjustments. This study provides data-driven treatment strategies based on genotype and identifies risk factors for specific AEs, contributing to a refined thiopurine treatment approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, 980-8574, Japan.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, 980-8574, Japan. ykakuta@med.tohoku.ac.jp.
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
- Center for Clinical Research and Education/Center for Inflammatory Bowel Disease, Hyogo Medical University, Nishinomiya, Japan.
- Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan.
ORCID-Profile: Yoichi Kakuta
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Makuuchi, M., Kakuta, Y., Umeno, J., Fujii, T., Takagawa, T., Ibuka, T., Miura, M., Sasaki, Y., Takahashi, S., Nakase, H., Kiyohara, H., Tominaga, K., Shimodaira, Y., Hiraoka, S., Ueno, N., Yanai, S., Yoshihara, T., Kakimoto, K., Matsuoka, K., …, & Masamune, A. (2024). Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02099-7
Vancouver
Makuuchi M, Kakuta Y, Umeno J, Fujii T, Takagawa T, Ibuka T, et al. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02099-7
BibTeX
@article{Makuuchi2024,
author = {Makuuchi, Motoki and Kakuta, Yoichi and Umeno, Junji and Fujii, Toshimitsu and Takagawa, Tetsuya and Ibuka, Takashi and Miura, Miki and Sasaki, Yu and Takahashi, Sakuma and Nakase, Hiroshi and Kiyohara, Hiroki and Tominaga, Keiichi and Shimodaira, Yosuke and Hiraoka, Sakiko and Ueno, Nobuhiro and Yanai, Shunichi and Yoshihara, Takeo and Kakimoto, Kazuki and Matsuoka, Katsuyoshi and Hayashi, Ryohei and Nanjo, Sohachi and Iwama, Itaru and Ishiguro, Yoh and Chiba, Hirofumi and Endo, Katsuya and Kagaya, Takashi and Fukuda, Tomohiro and Sakata, Yasuhisa and Kudo, Takahiro and Takagi, Tomohisa and Takahashi, Kenichi and Naganuma, Makoto and Shinozaki, Masaru and Ogata, Noriyuki and Tanaka, Hiroki and Narimatsu, Kazuyuki and Miyazaki, Haruka and Ishige, Takashi and Onodera, Motoyuki and Hashimoto, Yu and Nagai, Hiroshi and Shimoyama, Yusuke and Naito, Takeo and Moroi, Rintaro and Shiga, Hisashi and Post-MENDEL study group, Post-MENDEL study group and Kinouchi, Yoshitaka and Andoh, Akira and Hisamatsu, Tadakazu and Masamune, Atsushi},
title = {Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study},
journal = {Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s00535-024-02099-7}
}
EUVIMED